The NODE-302 open-label extension study examined the safety and efficacy of self-administered intranasal etripamil for treating recurrent episodes of paroxysmal supraventricular tachycardia (PSVT). Among 169 enrolled patients, 105 self-administered etripamil at least once, with a median follow-up of 232 days. The results showed a 60.2% probability of conversion to sinus rhythm within 30 minutes, with a median conversion time of 15.5 minutes. Patients who self-treated multiple episodes exhibited a consistent response, with 75% converting within 30 minutes on both episodes. Adverse events were reported by 42.9% of patients, primarily mild-to-moderate and transient, including nasal congestion and discomfort. Importantly, no serious cardiac safety events were noted within 24 hours of administration. The study concluded that etripamil nasal spray is a well-tolerated and effective self-treatment option for PSVT.